VIRBAC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 358 EUR | +2.73% |
|
+3.17% | -0.42% |
| May. 03 | VIRBAC : Virbac remains an attractive animal healthcare play |  |
| Apr. 17 | VIRBAC : A healthy start to 2024; outlook re-iterated | |
Presenter SpeechManuela Rodríguez;Investor Relations (Executives)Welcome to the 2019 half year...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Virbac specializes in the research, production and marketing of veterinary medicines. The activity is organized around 2 product families:
- pet medications: pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications: pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: France (15.4%), Europe (26.2%), Latin America (17.1%), Asia (16.4%), North America (13.2%), Pacific (9.3%), Africa and Middle East (2.4%).
Sector
Pharmaceuticals
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
358
EUR
Average target price
368
EUR
Spread / Average Target
+2.79%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.42% | 3.22B | |
| +13.36% | 8.33B | |
| +26.88% | 3.77B | |
| +9.80% | 1.56B | |
| -11.98% | 1.47B | |
| -23.69% | 1.28B | |
| -7.23% | 1.21B | |
| -7.75% | 1.21B | |
| +9.76% | 1.15B | |
| -18.23% | 883M |
- Stock Market
- Equities
- VIRP Stock
- News Virbac
- Transcript : Virbac SA, H1 2019 Earnings Call, Sep 17, 2019